Penetration of the blood–brain barrier and the anti-tumour effect of a novel PLGA-lysoGM1/DOX micelle drug delivery system. Issue 5 (29th January 2020)

• Record Type: Journal Article
• Authors: Yin, Ying; Wang, Jun; Yang, Meng; Du, Ruolin; Pontrelli, Giuseppe; McGinty, Sean; Wang, Guixue; Yin, Tieying; Wang, Yazhou
• Is Part Of: Nanoscale. Volume 12:Issue 5(2020)
• Page Start: 2946
• Page End: 2960
• Publication Date: 2020-01-29
• Subjects: Nanoscience -- Periodicals; Nanotechnology -- Periodicals; 620.505
• DOI: 10.1039/c9nr08741a
• Languages: English
• ISSNs: 2040-3364

Abstract

Abstract : a) Diagram depicting the preparation of drug delivery system of PLGA-lysoGM1/DOX micelles. b) Schematic illustration of micelles elicited antitumor. c) Micelles cross BBB via micropinocytosis and autophagy/lysosomal pathways. Abstract : Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the presence of the blood–brain barrier (BBB). A novel nano-delivery vehicle system composed of PLGA-lysoGM1/DOX micelles was developed to cross the BBB for CNS treatment. We have shown that doxorubicin (DOX) as a model drug encapsulated in PLGA-lysoGM1 micelles can achieve up to 3.8% loading efficiency and 61.6% encapsulation efficiency by the orthogonal test design. Our in vitro experiments demonstrated that PLGA-lysoGM1/DOX micelles had a slow and sustainable drug release under physiological conditions and exhibited a high cellular uptake through the macropinocytosis and the autophagy/lysosomal pathways. In vivo experimental studies in zebrafish and mice confirmed that PLGA-lysoGM1/DOX micelles could cross the BBB and be specifically accumulated in the brain. Moreover, an excellent anti-glioma effect was observed in intracranial glioma-bearing rats. Therefore, PLGA-lysoGM1/DOX micelles not only effectively can cross the BBB, but our results also suggest that they have great potential for anti-glioma therapy and other central nervous system diseases.